Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 dec 2014 - 07:47
Statutaire naam
Galapagos NV
Titel
Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Bericht
Mechelen, Belgium; 19 December 2014 - Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (e.g., G551D). In combination with corrector GLPG2222, this potentiator will also be developed for patients affected by the F508del mutation, the most prevalent mutation in CF patients. This achievement triggers a milestone payment of $10 million from AbbVie.
Datum laatste update: 21 februari 2026